These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33895825)

  • 1. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
    Jeong SH; Chung SJ; Yoo HS; Hong N; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
    Brain; 2021 May; 144(4):1127-1137. PubMed ID: 33895825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of statins on dopamine loss and prognosis in Parkinson's disease.
    Jeong SH; Lee HS; Chung SJ; Yoo HS; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
    Brain; 2021 Nov; 144(10):3191-3200. PubMed ID: 34347020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
    Brauer R; Wei L; Ma T; Athauda D; Girges C; Vijiaratnam N; Auld G; Whittlesea C; Wong I; Foltynie T
    Brain; 2020 Oct; 143(10):3067-3076. PubMed ID: 33011770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients.
    Lin YH; Hsu CC; Liu JS; Chang KC; Huang JA
    Sci Rep; 2023 Dec; 13(1):22489. PubMed ID: 38110464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease.
    Jung JH; Na HK; Jeong SH; Chung SJ; Yoo HS; Lee YH; Baik K; Kim SJ; Sohn YH; Lee PH
    Mov Disord; 2023 May; 38(5):843-853. PubMed ID: 36825772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.
    Bayram E; Litvan I
    Brain; 2020 Oct; 143(10):2868-2871. PubMed ID: 33103730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
    Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease.
    Maanvi ; Kumari S; Deshmukh R
    Eur J Pharmacol; 2023 Jan; 939():175426. PubMed ID: 36544303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease.
    Lee YH; Cha J; Chung SJ; Yoo HS; Sohn YH; Ye BS; Lee PH
    Sci Rep; 2019 Jul; 9(1):10531. PubMed ID: 31324895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of choroid plexus volume with motor symptoms and dopaminergic degeneration in Parkinson's disease.
    Jeong SH; Park CJ; Jeong HJ; Sunwoo MK; Ahn SS; Lee SK; Lee PH; Kim YJ; Sohn YH; Chung SJ
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1047-1055. PubMed ID: 37399288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's Disease, Diabetes and Cognitive Impairment.
    Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of GLP-1 agonists and DPP4 inhibitors.
    Tuch BE
    Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological function of dipeptidyl peptidase-4 on type 2 diabetes patients and diabetic mice.
    Qiao J; Li L; Ma Y; Shi R; Teng M
    Curr Res Transl Med; 2019 Aug; 67(3):89-92. PubMed ID: 30591375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
    Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F
    Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Rabizadeh S; Tavakoli Ardakani MA; Mouodi M; Bitaraf M; Shab-Bidar S; Esteghamati A; Nakhjavani M
    Adv Ther; 2020 Sep; 37(9):3660-3675. PubMed ID: 32671686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
    Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
    Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.